-
AI for Pricing Reimbursement: When to Green-Light, When to Red-Light?
Sep 9, 2025, 16:22 PM -
Environmental Impact of Psychiatric Outpatient Visit: Emissions Analysis of Travel and the Sustainability Potential of Remote Consultations
Sep 9, 2025, 16:22 PM -
Incidence and Treatment of Squamous-Cell Anal Cancer (SCAC) in Germany: A Retrospective Study in German Statutory Health Insurance (SHI) Claims Data
Sep 9, 2025, 16:22 PM -
Forecasting the Rise in Direct and Indirect Costs for Lung Cancer on the Example of Poland
Sep 9, 2025, 16:22 PM -
Use of AI in Breast Cancer Screening in England Has a Minimal Impact on Greenhouse Gas Emissions and May Increase Diagnostic Accuracy
Sep 9, 2025, 16:22 PM -
Hospital Burden of Pulmonary Arterial Hypertension in France: A Real-World Study Using the French Hospitalization Database (PMSI)
Sep 9, 2025, 16:22 PM -
Methodological Approach to Assess the Environmental Impact Analysis of Expanding Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in the Chronic Kidney Disease Patient Pathway: A French Perspective
Sep 9, 2025, 16:22 PM -
A Comprehensive Approach Including Mailed FITs and Nurse Navigation for Colorectal Cancer Screening
Sep 9, 2025, 16:22 PM -
Modeling the Public Health Impact of Nirsevimab and Maternal Vaccination With RSVpreF Against Infant Respiratory Syncytial Virus Infection in Germany
Sep 9, 2025, 16:22 PM -
Real-World Cost of Automated Red Blood Cell Exchange for Sickle Cell Disease in Kenya: A Cost-Reimbursement Gap Analysis From a Public Sector Perspective
Sep 9, 2025, 16:22 PM -
Integrating Stakeholder Willingness-to-Pay Using the Van Westendorp Price Sensitivity Meter Into Cost-Effectiveness Analysis: A Mixed-Methods Pricing Framework
Sep 9, 2025, 16:22 PM -
Evaluating Clinical Similarity: A Systematic Review of Methods Used Within National Institute for Health and Care Excellence (NICE) Cost-Comparison Evaluations (CCEs) When Relying on Statistically Nonsignificant Differences From Indirect Treatment...
Sep 9, 2025, 16:22 PM -
Fostamatinib-Induced Hepatomegaly: A Novel Signal Identified Through US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Sep 9, 2025, 16:22 PM -
Enhancing Healthcare Cost Communication Through Visualization: A Decision Tree Framework
Sep 9, 2025, 16:22 PM -
Navigating Implementation of the EU HTA Regulation for Medical Devices: Insights From National HTA Bodies Across Europe
Sep 9, 2025, 16:22 PM -
Care Partner Burden and Experiences With Schizophrenia: A National Canadian Survey
Sep 9, 2025, 16:22 PM -
AI for Rapid Data Extraction: A Case Study on the Economic and Caregiver Burden of Motor Neuron Disease
Sep 9, 2025, 16:22 PM -
Beyond the Conversation: A Narrative Review of Cost-Informed Shared Decision Making and Its Impact on Medication Adherence in Chronic Conditions
Sep 9, 2025, 16:22 PM -
How Do National Systems Take the JCA Into Account Navigating Specificities to Achieve Accelerated Patient Access?
Sep 9, 2025, 16:22 PM -
Incentivizing Access to New Drugs in Psychiatry: Exploration of a Subscription Payment Approach to Overcome Barriers to European Launch
Sep 9, 2025, 16:22 PM
